Meanwhile, in the CGRD cohort, 33 patients initially diagnosed with MS had received at least 30 days of DMT and were eventually reclassified to the NMOSD diagnosis with positive anti-AQP4 autoantibody test results. This evidence concerns the gene AQP4 and myeloid sarcoma.